![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/c/cd/Acalabrutinib.svg/640px-Acalabrutinib.svg.png&w=640&q=50)
Acalabrutinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Acalabrutinib?
Summarize this article for a 10 year old
Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL).[7] It may be used both in relapsed as well as in treatment-naive settings.[8]
![]() | |
Clinical data | |
---|---|
Trade names | Calquence |
Other names | ACP-196 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618004 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
ECHA InfoCard | 100.247.121 ![]() |
Chemical and physical data | |
Formula | C26H23N7O2 |
Molar mass | 465.517 g·mol−1 |
3D model (JSmol) | |
| |
|
Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells.[7] It is a second generation Bruton's tyrosine kinase inhibitor.[9][10] Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow.[5] By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.[5]
Acalabrutinib was approved for medical use in the United States in 2017,[7] and in the European Union in November 2020.[5]